Document is current

Article History

Accepted: 24 October 2020

First Online: 11 March 2021

Compliance with ethical standards

:

: RM (Roxana Mehran) has received institutional research grant support from AstraZeneca, Bayer, Beth Israel Deaconess Medical Center, Bristol-Myers Squibb, CSL Behring, Eli Lilly/Daiichi-Sankyo, Inc., Medtronic, Novartis Pharmaceuticals and OrbusNeich; has served on the executive committee of Janssen Pharmaceuticals and Osprey Medical Inc.; has served on the data safety monitoring board of Watermark Research Partners; has served as a consultant for Abbott Laboratories, Abiomed (Spouse), Boston Scientific, Cardiovascular Systems, Inc., Medscape, Siemens Medical Solutions, The Medicines Company (Spouse), Roivant Sciences, Inc, Volcano Corporation and Sanofi; has equity in Claret Medical Inc. and Elixir Medical Corporation. MK is a consultant and has received research grants from Abbott, Medtronic, OrbusNeich, Biosensors, and Boston Scientific. DJA has received payment as an individual for: a) Consulting fee or honorarium from Amgen, Aralez, AstraZeneca, Bayer, Biosensors, Boehringer Ingelheim, Bristol-Myers Squibb, Chiesi, Daiichi-Sankyo, Eli Lilly, Haemonetics, Janssen, Merck, PhaseBio, PLx Pharma, Pfizer, Sanofi, and The Medicines Company; b) Participation in review activities from CeloNova and St. Jude Medical; c) Institutional payments for grants from Amgen, AstraZeneca, Bayer, Biosensors, CeloNova, CSL Behring, Daiichi-Sankyo, Eisai, Eli-Lilly, Gilead, Idorsia, Janssen, Matsutani Chemical Industry Co., Merck, Novartis, Osprey Medical, and Renal Guard Solutions. SB serves on the advisory board/ received honoraria from Abbott Vascular, Biotronik, Amgen, Pfizer, Reata; has received research grants from Abbott Vascular and NHLBI. AS serves as an Advisory Board Member/Speaker’s bureau/received consulting honoraria – Abbott Vascular, Medtronic, Boston Scientific and Meril Lifesciences. DLB discloses the following relationships—Advisory Board: Cardax, Cereno Scientific, Elsevier Practice Update Cardiology, Medscape Cardiology, PhaseBio, PLx Pharma, Regado Biosciences; Board of Directors: Boston VA Research Institute, Society of Cardiovascular Patient Care, TobeSoft; Chair: American Heart Association Quality Oversight Committee; Data Monitoring Committees: Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute, for the PORTICO trial, funded by St. Jude Medical, now Abbott), Cleveland Clinic (including for the ExCEED trial, funded by Edwards), Duke Clinical Research Institute, Mayo Clinic, Mount Sinai School of Medicine (for the ENVISAGE trial, funded by Daiichi Sankyo), Population Health Research Institute; Honoraria: American College of Cardiology (Senior Associate Editor, Clinical Trials and News, <u>ACC.org</u>; Vice-Chair, ACC Accreditation Committee), Baim Institute for Clinical Research (formerly Harvard Clinical Research Institute; RE-DUAL PCI clinical trial steering committee funded by Boehringer Ingelheim; AEGIS-II executive committee funded by CSL Behring), Belvoir Publications (Editor in Chief, Harvard Heart Letter), Duke Clinical Research Institute (clinical trial steering committees, including for the PRONOUNCE trial, funded by Ferring Pharmaceuticals), HMP Global (Editor in Chief, Journal of Invasive Cardiology), Journal of the American College of Cardiology (Guest Editor; Associate Editor), Medtelligence/ReachMD (CME steering committees), MJH Life Sciences, Population Health Research Institute (for the COMPASS operations committee, publications committee, steering committee, and USA national co-leader, funded by Bayer), Slack Publications (Chief Medical Editor, Cardiology Today’s Intervention), Society of Cardiovascular Patient Care (Secretary/Treasurer), WebMD (CME steering committees); Other: Clinical Cardiology (Deputy Editor), NCDR-ACTION Registry Steering Committee (Chair), VA CART Research and Publications Committee (Chair); Research Funding: Abbott, Afimmune, Amarin, Amgen, AstraZeneca, Bayer, Boehringer Ingelheim, Bristol-Myers Squibb, Cardax, Chiesi, CSL Behring, Eisai, Ethicon, Ferring Pharmaceuticals, Forest Laboratories, Fractyl, Idorsia, Ironwood, Ischemix, Lexicon, Lilly, Medtronic, Pfizer, PhaseBio, PLx Pharma, Regeneron, Roche, Sanofi Aventis, Synaptic, The Medicines Company; Royalties: Elsevier (Editor, Cardiovascular Intervention: A Companion to Braunwald’s Heart Disease); Site Co-Investigator: Biotronik, Boston Scientific, CSI, St. Jude Medical (now Abbott), Svelte; Trustee: American College of Cardiology; Unfunded Research: FlowCo, Merck, Novo Nordisk, Takeda. JH is a consultant for Abbott. FJN reports that his institution has received research grants, consultancy fees and speaker honoraria from Daiichi Sankyo, Astra Zeneca, Sanofi-Aventis, Bayer, The Medicines Company, Bristol, Novartis, Roche, Boston Scientific, Biotronik, Medtronic and Edwards. KK serves as an advisory board member for Abbott Vascular Japan and receives honorarium for lectures. VR, KR and JW are employees of Abbott Vascular. All other authors report no relevant conflicts of interest.